LegoChem Bioscience said it has entered into a research collaboration and license option agreement to develop an antibody-drug conjugate (ADC) treatment with a Chinese biopharmaceutical firm.

However, the company did not name which Chinese company, citing a contractual term.

Under the accord, the two companies plan to discover ADC candidates by using the antibodies owned by the Chinese company and LegoChem's next-generation ADC platform technology. Legochem will also have a technology transfer option and exercise global development and commercialization rights for candidate materials jointly discovered with its Chinese counterpart.

"The Chinese company is the best partner with innovative R&D and rapid commercialization capabilities in the field of biopharmaceuticals," LegoChem President Kim Yong-zu said. "Through this partnership, we will be able to once again prove the value of Legochem's next-generation ADC platform as the world's best technology through the discovery and clinical development of competitive ADC therapeutics."